Francis Knuettel II - 14 Jun 2024 Form 4 Insider Report for Chromocell Therapeutics Corp (CHRO)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRO	Stock Options	Award		+27,778	+111%		52,778	14 Jun 2024	Common Stock	27,778	$1.30	Camden Capital LLC	F1, F2
transaction	CHRO	Stock Options	Award		+324,000	+614%		376,778	14 Jun 2024	Common Stock	324,000	$1.30	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	On June 14, 2024, Camden Capital LLC was granted stock options to purchase 27,778 shares of common stock at an exercise price of $1.30 per share, which were fully vested.
F2	The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.
F3	On June 14, 2024, the Reporting Person was granted stock options to purchase 324,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.